Understanding the Immune Landscape of Liver Cancer for Better Immunotherapy
Author Information
Author(s): Xue Jun, Yang Shuai, Zhang Si‐Si, Fan Jun, Wu Zi‐Long, Sui Cheng‐Jun, Yang Yong‐Qiang, Zhang Jin‐Feng, Liu Pian, Zhang De‐Jun, Qiu Xin‐Yao, Zhang Tao, Chen Lei, Wu Gang, Wang Hong‐Yang, Tang Jing
Primary Institution: Huazhong University of Science and Technology
Hypothesis
Can the immune characteristics of patients with unresectable primary liver cancer predict their response to immunotherapy?
Conclusion
The study identifies specific immune cell profiles that can help predict which liver cancer patients will respond to immunotherapy.
Supporting Evidence
- Responders had lower baseline B cell and HLA-DR+CD8+T cell proportions.
- Classical monocytes decreased more in responders after treatment.
- Responders showed higher enrichment of B cells in tumors compared to non-responders.
- A predictive model achieved a satisfactory AUC over 0.9 in independent cohorts.
- Dynamic changes in immune cell populations can indicate treatment response.
Takeaway
Doctors can look at certain immune cells in the blood of liver cancer patients to guess if their treatment will work.
Methodology
The study used single-cell mass cytometry and immunohistochemistry to analyze immune cells from blood and tumor samples of liver cancer patients.
Potential Biases
Potential biases may arise from the small sample size and the heterogeneity of the patient population.
Limitations
The study had a relatively small sample size and included different types of liver cancer, which may affect the results.
Participant Demographics
The study included 77 patients with unresectable primary liver cancer, primarily hepatocellular carcinoma.
Statistical Information
P-Value
0.039
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website